Tango Therapeutics(NASDAQ) TNGX

Tango Therapeutics creates drugs that find and kill cancer cells. These treatments target genetic changes to help specific groups of patients. They focus on killing tumors while sparing healthy cells.

Fighting Cancer with Precision

• Vopimetostat: Selective drug candidate targeting cancers with specific genetic deletions; currently in clinical trials as a single agent and combination therapy.
• TNG456: Brain-penetrant candidate designed for central nervous system cancers; currently enrolling patients with solid tumors and glioblastoma.
• Precision Oncology Programs: Research efforts identifying targets where a genetic loss makes cancer cells vulnerable to specific drugs.

Strategic Deals and Partnerships

• Expanded its partnership with Gilead Sciences, Inc. in August 2020 to develop a pipeline of cancer therapies.
• Formed a supply agreement with Revolution Medicines, Inc. in November 2024 for combination drug trials.
• Joined with Erasca, Inc. in March 2026 to study vopimetostat with a pan-RAS molecular glue.
• Shortened the research term with Gilead Sciences, Inc. in August 2025 to conclude the research portion of their agreement.

Selective Targeting Technology

The company uses a discovery platform to find targets where a specific genetic loss makes cancer cells vulnerable to certain drugs. This approach, known as synthetic lethality, aims to kill tumor cells while minimizing damage to healthy tissue.

Performance by the Numbers

• Revenue was $0 in Q1 2026, down 100% from $5.4 million in Q1 2025.
• Net loss deepened to $45.5 million in Q1 2026, worsening 14.1% from the previous year.
• Free cash flow deficit deepened to $44.4 million in Q1 2026, a 6.3% decrease in performance.
• Total cash and marketable securities were $379.8 million as of March 31, 2026.
• Market cap hit $3 billion in Q1 2026, up from $151.1 million in Q1 2025.

Bottom Line

Tango has evolved from a discovery platform into a clinical-stage biotech focused on its core cancer-fighting programs. This transition involves prioritizing resources toward its most advanced protein arginine methyltransferase 5 treatments.